Several other research analysts have also issued reports on DHR. Deutsche Bank lowered their price target on shares of Danaher from $114.00 to $107.00 and set a buy rating for the company in a report on Thursday, March 1st. Royal Bank of Canada reiterated a hold rating and issued a $98.00 price objective on shares of Danaher in a research note on Wednesday, January 31st. Stifel Nicolaus reissued a buy rating and issued a $110.00 price target on shares of Danaher in a research report on Friday, January 19th. Morgan Stanley lifted their price target on shares of Danaher from $103.00 to $110.00 and gave the company an overweight rating in a research report on Wednesday, January 31st. Finally, Cowen reaffirmed a buy rating and set a $110.00 price objective on shares of Danaher in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $101.40.
Shares of DHR stock opened at $101.93 on Friday. Danaher has a one year low of $78.97 and a one year high of $104.82. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market cap of $71,103.26, a PE ratio of 28.88, a price-to-earnings-growth ratio of 2.14 and a beta of 1.03.
The company also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Thursday, March 29th will be paid a $0.16 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $0.64 annualized dividend and a yield of 0.63%. This is a positive change from Danaher’s previous quarterly dividend of $0.14. Danaher’s dividend payout ratio is currently 15.86%.
In other news, EVP William K. Daniel sold 131,066 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the completion of the sale, the executive vice president now owns 270,523 shares of the company’s stock, valued at $27,606,872.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Daniel L. Comas sold 62,989 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $101.96, for a total value of $6,422,358.44. Following the sale, the chief financial officer now directly owns 227,805 shares of the company’s stock, valued at approximately $23,226,997.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 313,260 shares of company stock valued at $31,657,786. Insiders own 12.20% of the company’s stock.
Several institutional investors have recently made changes to their positions in DHR. Point72 Asset Management L.P. raised its holdings in shares of Danaher by 276.8% during the third quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock valued at $225,332,000 after acquiring an additional 1,929,751 shares in the last quarter. BlackRock Inc. raised its holdings in Danaher by 4.6% in the fourth quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock worth $3,804,169,000 after purchasing an additional 1,789,474 shares in the last quarter. Findlay Park Partners LLP raised its holdings in Danaher by 52.9% in the third quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after purchasing an additional 1,425,000 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Danaher by 86.1% in the third quarter. JPMorgan Chase & Co. now owns 3,011,947 shares of the conglomerate’s stock worth $256,136,000 after purchasing an additional 1,393,165 shares in the last quarter. Finally, Evercore Trust Company N.A. bought a new position in Danaher in the third quarter worth $113,606,000. Institutional investors own 77.64% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was posted by BBNS and is owned by of BBNS. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/03/19/danaher-dhr-earns-neutral-rating-from-credit-suisse-group/2016657.html.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.